Chordoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Radiotherapy does not reduce mortality, local recurrence in resected sacral chordoma - Healio



Radiotherapy does not reduce mortality, local recurrence in resected sacral chordoma 
Healio
WAILEA, Hawaii ? Preoperative radiotherapy did not reduce risk for mortality, local tumor recurrence or metastasis among patients who underwent surgical treatment for sacral chordoma, according to study results presented at Connective Tissue Oncology ...

 


Retired lawyer organizes fundraising jazz concert for cancer research - The Lawyer's Daily



The Lawyer's Daily
 
Retired lawyer organizes fundraising jazz concert for cancer research 
The Lawyer's Daily
In researching the disease, Golick encountered a U.S.-based not-for-profit foundation that was working on chordoma research. He developed ties with the foundation and put together a fundraising concert in New York on behalf of the foundation. While he ...

 


Tazemetostat Active in Rare Pediatric Solid Tumors - Cancer Network



Tazemetostat Active in Rare Pediatric Solid Tumors 
Cancer Network
Children with relapsed or refractory INI1-deficient malignant rhabdoid tumors, epithelioid sarcomas, or poorly differentiated chordomas tolerated treatment with the investigational drug tazemetostat well, with several patients experiencing responses ...
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative ... Nasdaq

all 3 news articles » 


Chordoma Global Clinical Trials Review, H1, 2017 - Research and Markets - Business Wire (press release)



Chordoma Global Clinical Trials Review, H1, 2017 - Research and Markets 
Business Wire (press release)
The clinical trial report provides an overview of Chordoma clinical trials scenario. This report provides top line data relating to the clinical trials on Chordoma. Report includes an overview of trial numbers and their average enrollment in top ...

and more » 


Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 - Nasdaq



Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 
Nasdaq
The company has also added a separate cohort to enroll adults with chordoma, due to the high rate of enrollment of these patients in the other INI1-negative cohort and the observed clinical activity with tazemetostat in this tumor type in both adults ...

and more » 


Globeimmune Cm (NASDAQ:GBIM) Experiences Heavier than Usual Trading Volume - Finance Daily



Globeimmune Cm (NASDAQ:GBIM) Experiences Heavier than Usual Trading Volume 
Finance Daily
The Business's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, which is in Phase II for the treatment of chordoma, and GI-4000, which is in Phase IIb for the treatment of ...

and more » 


New Drug Hope for Rare Bone Cancer Patients - Drug Discovery & Development



Drug Discovery & Development
 
New Drug Hope for Rare Bone Cancer Patients 
Drug Discovery & Development
Patients with a rare bone cancer of the skull and spine - chordoma - could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital ...

 


Globeimmune Cm (NASDAQ:GBIM) Experiences Heavier than Average Trading Volume - HugoPress



Globeimmune Cm (NASDAQ:GBIM) Experiences Heavier than Average Trading Volume 
HugoPress
The Business's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, which is in Phase II for the treatment of chordoma, and GI-4000, which is in Phase IIb for the treatment of ...

 


Epizyme Reports Third Quarter 2017 Operating Results and Company Updates - Markets Insider



Wolcott Daily
 
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 
Markets Insider
Objective responses were observed in patients with epithelioid sarcoma (n=1), poorly differentiated chordoma (n=2) and atypical teratoid rhabdoid tumors (n=1) at dose levels ranging from 520 to 900 mg/m2 twice daily. Enrollment in the dose-expansion ...
Epizyme, Inc. - EPZM - Stock Price Today - Zacks Zacks Investment Research

all 39 news articles » 


Globeimmune Cm (NASDAQ:GBIM) Sees Unusual Trading Volume in Its Shares - First News 24



Globeimmune Cm (NASDAQ:GBIM) Sees Unusual Trading Volume in Its Shares 
First News 24
The Business's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, which is in Phase II for the treatment of chordoma, and GI-4000, which is in Phase IIb for the treatment of ...

and more »